Current data on vigabatrin;Datos actuales sobre la vigabatrina

Revista de Neurologia

Volumn 30, Issue SUPPL. 1, 2000, Pages

  Casas Fernandez C ^a  

^a Hospital Universitario Virgen de la Arrixaca ^*  (Spain)

Author keywords

Pharmacodynamic; Pharmacokinetic; Vigabatrin; Visual fields; West's syndrome

Indexed keywords

VALPROIC ACID; VIGABATRIN;

CONFERENCE PAPER; EPILEPSY; PHARMACODYNAMICS; RISK BENEFIT ANALYSIS; SEIZURE; VISUAL FIELD; WEST SYNDROME;

ANTICONVULSANTS; EPILEPSY; HUMANS; VIGABATRIN; VISUAL FIELDS;

EID: 0033944350     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (59)

1. Herranz JL, Arteaga R, Armijo JA. Nuevos antiepilépticos: vigabatrina, lamotrigina y felbamato. Neurologia 1994; 9: 410-7.
2. Herranz JL. Ventajas e inconvenientes de los nuevos antiepilépticos. Rev Neurol 1996; 24: 1426-34.
3. Grippo J. Tratamiento de la epilepsia: nuevas drogas. Rev Neurol 1996; 24: 1435-40.
4. Jung MJ, Palfreyman MG. Vigabatrin. Mechanisms of action. In Levy RH, Mattson RH, Meldrum BS, eds. Antiepileptic drugs. 4 ed. New York: Raven Press; 1995. p. 903-13.
5. Ben-Menachen E. Vigabatrin. Chemistry, absorption, distribution, and elimination. In Levy RH, Mattson RH, Meldrum BS, eds. Antiepileptic drugs. 4 ed. New York: Raven Press; 1995. p. 915-23.
6. Mueller SG, Trabesinger AH, Weber OM, et al. Brain GABA, vigabatrin, and responder identification: a magnetic resonance spectroscopy study. Epilepsia 1998; 39 (Suppl 2): S6.
7. Armijo JA, Cuadrado A. Bases farmacodinámicas para la asociación de antiepilépticos. Rev Neurol 1997; 25 (Supl 4): S363-73.
8. Arroyo S, Campistol J, Comes E, Fossas P, Martínez I, Padró Ll, et al. El tratamiento de las epilepsias. Guía terapéutica de la Societal Catalana de Neurologia. Rev Neurol 1999; 29: 754-66.
9. Kälviäinen R, Mervaaia E, Sivenius J, et al. Vigabatrin. Clinical use. In Levy RH, Mattson RH, Meldrum BS, eds. Antiepileptic drugs. 4 ed. New York: Raven Press; 1995. p. 925-30.
10. Armijo JA, Adín J. Bases farmacocinéticas para la asociación de antiepilépticos. Rev Neurol 1997; 25 (Supl 4): S382-95.
11. Armijo JA. ¿Qué fármacos deben seleccionarse en cada tipo de epilepsia? Rev Neurol 1997; 25: 356-66.
12. Herranz JL, Campos J, Casas C, et al. Spanish experience with efficacy and tolerability of vigabatrin in 197 children with refractary epilepsy. Epilepsia 1995; 36 (Suppl 3): S103.
13. Jedrzejczak J, Owczarek K, Zwolinski P. Long-term safety and efficacy of vigabatrin in drug resistant epilepsy. Epilepsia 1999; 40 (Suppl 2): S287.
14. Kaczynska H. Vigabatrin as add-on therapy in drug-refractory epilepsy in mentally retarded and multiply handicapped (MRMH) patients: a 1-year follow-up study. Epilepsia 1998; 39 (Suppl 2): S41.
15. Garofalo PG, Durisotti C, Toso V. Long-term follow-up of vigabatrin add-on therapy-epilepsy Centre of Vicenza Hospital. Epilepsia 1998; 39 (Suppl 2): S41.
16. Parmeggiani A, Onorato S, Posar A, et al. Vigabatrin monotherapy in benign partial epilepsy with centrotemporal spikes. Epilepsia 1998; 39 (Suppl 2): S41.
17. Veggioti P, Granocchio E, Fazzi E, et al. Partial seizures in the first year of life: treatment with vigabatrin. Epilepsia 1998; 39 (Suppl 2): S41.
18. Marson AG, Kadir ZA, Chadwick DW. The new antiepileptic drugs. A systematic review oh their efficacy and tolerability. Epilepsia 1997; 38: 859-80.
19. Caviedes BE, Herranz JL, Arteaga R, Armijo JA. En niños con epilepsias rebeldes, ¿vigabatrina o lamotrigina? Rev Neurol 1999; 28: 444-8.
20. Casas C, Areas J, Arteaga R, Castro-Gago M, Domingo R, Eiris J, et al. Espasmos infantiles. Tratamiento con vigabatrina. Análisis retrospectivo multicéntrico de resultados. Rev Neurol 1995; 23: 1258.
21. Aicardi J, Sabril IS, investigator and peer review groups, Mumford JP, Dumas C, Wood S. Vigabatrin as initial therapy for infantile spasms: a European retrospective survey. Epilepsia 1996; 37: 638-42.
22. Prats-Viñas JM, Garaizar-Axpe C. Espasmos infantiles (síndrome de West): características y opciones terapéuticas. Rev Neurol 1996; 24: 1411-4.
23. Fisher RS, Kerrigan III JF. Vigabatrin. Toxicity. In Levy RH, Mattson RH, Meldrum BS, eds. Antiepileptic drugs. 4 ed. New York: Raven Press; 1995. p. 931-9.
24. Ferrie CD, Robinson RO, Panayiotopoulos CP. Psychotic and severe behavioral reactions with vigabatrin: a review. Acta Neurol Scand 1996; 93: 1-8.
25. Argumosa A, Herranz JL, Arteaga R, Barrasa J, Calles L, Armijo J. Vigabatrina y alteración del campo visual. Rev Neurol 1999; 28: 741-5.
26. Agosti R, Yasargil G, Egli M, et al. Neuropathology of a human hippocampus following long-term treatment with vigabatrin: lack of microvacuoles. Epilepsy Res 1990; 6: 166-70.
27. Eke T, Talbot JF, Lawden MC. Severe persistent visual field constriction associated with vigabatrin. Br Med J 1997; 314: 180-1.
28. Steinhoff BJ, Freudenthaler N, Paulus W. The influence of established and new antiepileptic drugs on visual perception. I. A placebo-controlled, double-blind, single-dose study in healthy volunteers. Epilepsy Res 1997; 29: 35-47.
29. Steinhoff BJ, Freudenthaler N, Paulus W. The influence of established and new antiepileptic drugs on visual perception. II. A controlled study in patients with epilepsy under long-term antiepileptic medication. Epilepsy Res 1997; 29: 49-58.
30. Tiel-Wilck, Jokiel B, Zinser P, et al. Afferent visual function after single dose application of γ-vinyl GABA. Neuro-ophtalmology 1995; 15: 305-10.
31. Schmidt T, Schmitz B, Jokiel B, et al. Constriction of the visual field in epilepsy patients taking vigabatrin and other antiepileptic drugs: a longitudinal study. Epilepsia 1999; 40 (Suppl 2): S256.
32. Roubertie A, Bellet H, Echenne B. Vigabatrin-associated retinal cone system dysfunction [Letter]. Neurology 1998; 51: 1779.
33. Krauss GL, Johnson MA, Miller NR. Vigabatrin-associated retinal cone system dysfunction. Electroretinogram and ophthalmologic findings. Neurology 1998; 50: 614-8.
34. Kraus GL, Johnson MA, Paul SR. Electroretinogram (ERG) and ophthalmologic findings in patients treated with vigabatrin. Epilepsia 1998; 39 (Suppl 6): S72.
35. Pung T, Ruether K, Schmitz B, et al. Visual field constriction during treatment with vigabatrin. Epilepsia 1998; 39 (Suppl 2): S40.
36. Mackenzie R, Klistorner A. Severe persistent visual field constriction associated with vigabatrin. Asymptomatic as well as symptomatic defects occur with vigabatrin [Letter]. Br Med J 1998; 316: 233.
37. Arndt CF, Derambure P, Defoort S, et al. Is visual impairment related to vigabatrin reversible? Epilepsia 1999; 40 (Suppl 2): S256.
38. Koehler J, Thömke F, Tettenbom B, et al. Influence of new antiepileptic drugs on visual evoked potentials and electroretinogram. Epilepsia 1999; 40(Suppl 2): S288.
39. Brigell MG. Vigabatrin-associated retinal cone system dysfunction [Letter]. Neurology 1998; 51: 1779.
40. Harding GFA. Severe persistent visual field constriction associated with vigabatrin. Four possible explanations exist [Letter]. Br Med J 1997; 314: 1694.
41. Krauss GL, Johnson MA, Miller NR. Vigabatrin-associated retinal cone system dysfunction [Reply from the authors]. Neurology 1998; 51: 1779-81.
42. Wilson EA, Brodie MJ. Severe persistent visual field constriction associated with vigabatrin. Chronic refractory epilepsy may have role in causing these unusual lesions [Letter]. Br Med J 1997; 314: 1693.
43. Harding GFA. Severe persistent visual field constriction associated with vigabatrin. Benefit: risk ratio must be calculated for individual patients [Letter]. Br Med J 1998; 316: 232.
44. Leach JP, Rao P, Ahlfat F, et al. Vigabatrin and visual field defects: is there a link? Epilepsia 1998; 39 (Suppl 6): S58.
45. Krämer G, Scollo-Lavizarri G, Jallon P, et al. Vigabatrin (VGB)-associated bilateral peripheral visual field defects: observations in seven patients and a pathophysiological hypothesis. Eur J Neurol 1998; 5 (Suppl 3): S216.
46. Kälviäinen R, Nousiainen I, Nikoskelainen, et al. Visual field defects associated with initial vigabatrin monotherapy as compared with initial carbamazepine monotherapy. Epilepsia 1998; 39 (Suppl 2): S5.
47. Backstrom JT. Severe persistent visual field constriction associated with vigabatrin. Manufactures have started several studies [Letter]. Br Med J 1997; 314: 1694.
48. Black AB. Vigabatrin and visual field loss. Epilepsia 1998; 39 (Suppl 2): S5.
49. Kälviäinen R, Nousiainen I, Mantyjarvi M, et al. Initial vigabatrin monotherapy is associated with increased risk of visual field constriction: a comparative follow-up study with patients on initial carbamazepine monotherapy and healthy controls. Epilepsia 1998; 39 (Suppl 6): S72.
50. Lawden MC, Eke T, Degg C, et al. Visual field constriction associated with vigabatrin treatment. Epilepsia 1999; 40 (Suppl 2): S256.
51. Krämer G, Scollo-Lavizzari G, Jallon P, et al. Vigabatrin-associated bilateral concentric visual field defects in four patients. Epilepsia 1997; 38 (Suppl 8): S179.
52. Schmitz B, Jokiel B, Schmidt T, et al. Visual field defects under treatment with vigabatrin (VGB), carbamazepine (CBZ) and valproate (VPA): a prospective study. Epilepsia 1999; 40 (Suppl 2): S257.
53. Beran RG, Curie J, Sandbach J, et al. Visual field restriction with new antiepileptic medication. Epilepsia 1998; 39 (Suppl 2): S6.
54. Baulac M, Nordmann JP, Lanoe Y, et al. Visual field (VF) constriction: one case associated with progabide and phenobarbital and three cases of worsening preexisting VF defects in presence of vigabatrin. Epilepsia 1998; 39 (Suppl 6): S46.
55. Paul SR, Krauss GL, Johnson MA, et al. Progression and recovery of visual function in patients treated with vigabatrin. Epilepsia 1999; 40 (Suppl 2): S287.
56. Versino M, Veggiotti P. Reversibility of vigabatrin-induced visual-field defect. Lancet 1999; 354: 486.
57. Wong ICK, Mawer GE. Severe persistent visual field constriction associated with vigabatrin. Reaction might be dose dependent [Letter]. Br Med J 1997; 314: 1693.
58. Beck RW. Vigabatrin-associated retinal cone system dysfunction [Letter]. Neurology 1998; 51: 1778-9.
59. Casas-Fernández C. Experiencia con el cuestionario de calidad de vida en el niño con epilepsia (CAVE). Rev Neurol 1997; 25: 415-21.